Last 37 quarters of trend data · Healthcare · Diagnostics & Lab Testing
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -41.81 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 15.64 | 16.60 | 14.79 | 10.05 | 11.68 | 7.38 | 6.96 | 6.48 | 4.68 | 3.69 | 4.99 | 3.73 | 5.17 | 6.10 | 7.10 | 4.67 | 5.49 | 11.72 | 9.43 | 17.55 | 23.52 |
| — | +125.0% | +112.6% | +55.0% | +149.4% | +100.3% | +39.5% | +74.0% | -9.4% | -39.6% | -29.7% | -20.3% | -5.9% | -48.0% | -24.7% | -73.4% | -76.6% | -64.9% | -72.4% | -64.2% | -42.8% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | 36.77 | 20.20 | 15.29 | 13.31 | — | 46.33 | 33.02 | 12.90 | 12.66 | 15.77 |
| — | — | — | — | — | — | — | — | — | — | — | — | -56.4% | -53.7% | +3.1% | — | +193.8% | +100.2% | -13.0% | -25.6% | +65.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.5% | 65.4% | 65.4% | 65.2% | 64.6% | 64.7% | 65.0% | 63.3% | 61.6% | 61.1% | 59.1% | 61.2% | 152.3% | 59.7% | 60.7% | 58.8% | 62.9% | 65.5% | 66.3% | 66.7% | 69.1% |
| — | +1.1% | +0.6% | +3.1% | +5.0% | +5.9% | +9.9% | +3.3% | -59.6% | +2.3% | -2.6% | +4.2% | +142.3% | -8.8% | -8.5% | -11.9% | -9.0% | -2.9% | -1.7% | +5.1% | +8.4% | |
| Operating Margin | -44.5% | -36.8% | -38.5% | -40.2% | -43.0% | -37.3% | -45.9% | -54.6% | -62.4% | -61.3% | -56.8% | -59.2% | -127.4% | -79.4% | -87.2% | -104.1% | -115.2% | -123.2% | -119.4% | -128.3% | -90.8% |
| — | +1.5% | +15.9% | +26.3% | +31.2% | +39.1% | +19.2% | +7.8% | +51.0% | +22.8% | +34.9% | +43.2% | -10.6% | +35.5% | +27.0% | +18.9% | -26.8% | -8.8% | -12.6% | +6.4% | +22.0% | |
| Net Margin | -42.4% | -34.5% | -35.9% | -37.2% | -45.7% | -35.0% | -43.0% | -46.8% | -55.0% | -56.3% | -57.9% | -68.2% | -120.6% | -60.2% | -53.1% | -103.7% | -110.3% | -138.0% | -210.2% | -128.2% | -84.1% |
| — | +1.5% | +16.7% | +20.6% | +16.9% | +37.9% | +25.7% | +31.5% | +54.4% | +6.5% | -9.1% | +34.2% | -9.4% | +56.4% | +74.8% | +19.1% | -31.1% | -21.6% | -98.4% | +8.0% | +29.7% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | -307.9% | -101.3% | -96.7% | -33.1% | -58.6% | -1708.8% | -123.3% | -66.7% | -53.8% | -20.9% | -12.9% |
| — | — | — | — | — | — | — | — | — | — | -425.0% | +94.1% | +21.6% | +50.4% | -8.9% | -8067.9% | -859.0% | -401.2% | -384.0% | -115.8% | -71.8% | |
| ROA | -23.8% | -6.5% | -6.3% | -5.7% | -7.8% | -7.1% | -7.5% | -6.7% | -7.3% | -6.8% | -6.2% | -6.6% | -10.4% | -4.7% | -4.3% | -8.6% | -8.5% | -9.1% | -11.5% | -5.7% | -4.1% |
| — | +7.9% | +15.9% | +15.2% | -6.4% | -3.8% | -20.5% | -2.1% | +29.7% | -44.6% | -42.6% | +23.0% | -23.5% | +48.0% | +62.3% | -50.5% | -105.9% | -91.4% | -173.8% | -19.7% | +22.6% | |
| ROIC | -34.5% | -24.6% | -20.3% | -10.3% | -11.2% | -18.8% | -21.1% | -16.2% | -15.0% | -19.7% | -25.5% | -22.5% | -19.6% | -6.8% | -7.2% | -8.4% | -8.2% | -7.6% | -6.9% | -6.5% | -5.2% |
| — | -31.1% | +3.9% | +36.4% | +25.5% | +4.6% | +17.4% | +27.9% | +23.8% | -190.0% | -253.3% | -166.7% | -139.3% | +10.5% | -4.2% | -30.4% | -57.3% | -20.4% | -25.5% | -10.4% | +7.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | 19.73 | 8.53 | 5.95 | 4.65 | — | 22.75 | 8.24 | 4.32 | 2.58 | 2.13 |
| — | — | — | — | — | — | — | — | — | — | — | — | -62.5% | -27.8% | +7.8% | — | +968.3% | +365.9% | +170.3% | +73.5% | +237.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.84 | 3.60 | 4.03 | 4.68 | 4.84 | 3.50 | 3.71 | 4.11 | 4.68 | 6.22 | 6.40 | 5.95 | 6.54 | 5.94 | 6.96 | 5.41 | 6.17 | 6.46 | 6.18 | 4.87 | 5.72 |
| — | +2.9% | +8.7% | +14.0% | +3.5% | -43.7% | -42.1% | -31.0% | -28.5% | +4.6% | -8.0% | +9.9% | +6.1% | -8.0% | +12.5% | +11.2% | +7.8% | -58.5% | -68.4% | -77.1% | -79.8% | |
| Quick Ratio | 4.56 | 3.35 | 3.71 | 4.39 | 4.56 | 3.12 | 3.35 | 3.76 | 4.36 | 5.85 | 6.07 | 5.66 | 6.24 | 5.60 | 6.65 | 5.18 | 5.90 | 6.10 | 5.83 | 4.71 | 5.57 |
| — | +7.5% | +10.8% | +16.7% | +4.5% | -46.7% | -44.7% | -33.5% | -30.1% | +4.5% | -8.8% | +9.2% | +5.8% | -8.2% | +14.2% | +10.1% | +6.0% | -60.2% | -69.8% | -77.6% | -80.1% | |
| Interest Coverage | -106.14 | -91.21 | -88.12 | -81.93 | -109.36 | -97.19 | -100.59 | -118.94 | -169.99 | -165.76 | -157.91 | -176.64 | -289.83 | -131.94 | -111.05 | -205.98 | -215.35 | -250.36 | -354.02 | -190.39 | -111.44 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 37 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GH stock.
Guardant Health, Inc.'s current P/E is -41.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Guardant Health, Inc.'s current operating margin is -44.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Guardant Health, Inc.'s business trajectory between earnings reports.